Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ARIXTRA
- Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)
- Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19
- Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
- Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty
- Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia
- ARIXTRA® Adherence in SVT Patients.
- Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
- Fondaparinux in Critically Ill Patients With Renal Failure
- Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)
- Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment
- Fondaparinux EU-RMP (Adherence)
- Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery
- Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)
- The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery
- "Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
- Hemorrhage Risk Prescribed Arixtra
- Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency
- Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm
- The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty
- Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients
- Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures
- Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery
- Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
- Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression
- Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)
- Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy
- The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients
- Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients
- Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients
- Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction
- Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer
- Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI
- Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
- Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers
- Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication
- Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism
- Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
- ARIXTRA Local Study For Registration In China.
- Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.
- A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)
Clinical trials list
click for details